For clinical use, simian adenoviruses are now widely regarded as one of the most effective means to induce CD8+ T cell responses, and ChAd-based vaccines against malaria, TB, HCV, HIV, Ebola, and Rift Valley fever are in clinical development [33, 37, 40, 42, 59]. The gene discussed is CD8A; the disease is Ebola hemorrhagic fever.